| Similar Articles |
|---|
 |
The Motley Fool
July 27, 2011 |
eResearch Technology Earnings Preview eResearch Technology will unveil its latest earnings on Monday, August 1. Analysts strongly back eResearch Technology.   |
The Motley Fool
February 10, 2005
Stephen D. Simpson |
eResearch Regains Heartbeat Increased FDA and consumer worries about cardiac safety should continue to fuel the cardiac researcher's growth. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
July 22, 2011 |
Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again. |
The Motley Fool
January 25, 2006
Brian Gorman |
PAREXEL Recovers The clinical research services company is in better shape, but it still has progress to make. Investors should approach the company with some caution. |
The Motley Fool
October 24, 2005
Brian Gorman |
PAREXEL Gets Squeezed First-quarter results reflect tough competition in the contract research industry. For now, this may be one stock to avoid. |
The Motley Fool
June 15, 2006
Brian Gorman |
Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note. |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
April 28, 2006
Brian Gorman |
Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note. |
The Motley Fool
June 10, 2005
Brian Gorman |
PAREXEL's New Risk The contract pharmaceutical research services provider is realigning its business, but even with reduced U.S. operations, it faces increased risk. Investors, beware. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
August 11, 2006
Brian Gorman |
PAREXEL Takes It Up a Notch The company reported higher profitability in the fourth quarter, and management expects the trend to continue. Investors, is this worth a closer look? |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
January 25, 2007
Brian Gorman |
Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year. |
The Motley Fool
January 10, 2006
Stephen D. Simpson |
Can ICON Be a Paragon of Growth? The clinical research organization specialist and stock have recovered from some troubles, but do current valuations leave much on the table? |
The Motley Fool
April 25, 2005
Brian Gorman |
Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar. |
The Motley Fool
March 20, 2006
Brian Gorman |
Much Ado About PAREXEL The contract research services provider's shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense. Investors, take note. |
The Motley Fool
October 21, 2005
Brian Gorman |
Covance Keeps Delivering Investors seemed to fret over the drug-development services company's full-year earnings forecast, but the facts suggest that Covance remains a solid long-term bet. |
